PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15110846-5 2004 (1S,2S)-2-Fluoro-2-phenylcyclopropylamine was a more potent inhibitor of both MAO A and B than was the (1R,2R)-enantiomer, indicating that the presence of fluorine has no influence on the enantioselectivity of MAO inhibition, since a similar effect of stereochemistry has been reported for tranylcypromine. Tranylcypromine 290-305 monoamine oxidase A Homo sapiens 78-83 33651656-2 2021 Tranylcypromine (TCP), an irreversible monoamine oxidase (MAO)-A/B inhibitor applied in treatment resistant depression, was not included because of strict requirements for quality of study design. Tranylcypromine 0-15 monoamine oxidase A Homo sapiens 39-66 9829163-3 1998 While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine is ingested, the selective monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl) and, even more so, the selective and reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide, are free from this potential interaction. Tranylcypromine 82-97 monoamine oxidase A Homo sapiens 320-339 9829163-3 1998 While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine is ingested, the selective monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl) and, even more so, the selective and reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide, are free from this potential interaction. Tranylcypromine 82-97 monoamine oxidase A Homo sapiens 341-346 29031059-2 2017 Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1. Tranylcypromine 0-15 monoamine oxidase A Homo sapiens 74-100 31291555-9 2019 In addition, our results indicated that the expression and catalytic activity of MAO-A were up-regulated by RANKL stimulation and down-regulated by TCP in vitro and in vivo. Tranylcypromine 148-151 monoamine oxidase A Homo sapiens 81-86 31291555-10 2019 Furthermore, the effects of MAO-A knockdown on OC differentiation indicated that MAO-A played an important role in osteoclastogenesis in vitro and might contribute to the inhibitory effects of TCP. Tranylcypromine 193-196 monoamine oxidase A Homo sapiens 28-33 31291555-10 2019 Furthermore, the effects of MAO-A knockdown on OC differentiation indicated that MAO-A played an important role in osteoclastogenesis in vitro and might contribute to the inhibitory effects of TCP. Tranylcypromine 193-196 monoamine oxidase A Homo sapiens 81-86 30242487-2 2018 The monoamine oxidases A and B (MAOA/MAOB) are prime candidates for the investigation into the role of DNA methylation in mental disorders, given their pivotal role in the metabolism of monoamines and as pharmacological targets of potent antidepressant drugs such as tranylcypromine, phenelzine or moclobemide. Tranylcypromine 267-282 monoamine oxidase A Homo sapiens 32-36 29031059-2 2017 Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1. Tranylcypromine 0-15 monoamine oxidase A Homo sapiens 102-107 29031059-2 2017 Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1. Tranylcypromine 17-20 monoamine oxidase A Homo sapiens 74-100 29031059-2 2017 Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1. Tranylcypromine 17-20 monoamine oxidase A Homo sapiens 102-107 28579071-3 2017 The irreversible and nonselective MAO-A/B inhibitor TCP has been confirmed as an efficacious and safe antidepressant drug. Tranylcypromine 52-55 monoamine oxidase A Homo sapiens 34-39 28579071-6 2017 Controlled studies revealed that TCP might provide a special advantage in the treatment of atypical depression, which was supported by a recent PET study of MAO-A activity in brain. Tranylcypromine 33-36 monoamine oxidase A Homo sapiens 157-162 28655495-3 2017 Pharmacological data of this review part I characterize TCP as an irreversible and nonselective MAO-A/B inhibitor at low therapeutic doses of 20mg/day with supplementary norepinephrine reuptake inhibition at higher doses of 40-60mg/day. Tranylcypromine 56-59 monoamine oxidase A Homo sapiens 96-103 24601544-4 2014 Docking and molecular dynamics were used to explore how 2-(2-benzofuranyl)-2-imidazoline hydrochloride (2-BFI) binds to MAO A and to explain why tranylcypromine increases tight binding to MAO B. Tranylcypromine 145-160 monoamine oxidase A Homo sapiens 120-125 24601544-5 2014 The energy for 2-BFI binding to MAO A was comparable to that for tranylcypromine-modified MAO B, but the location of 2-BFI in the MAO A could be anywhere in the monopartite substrate cavity. Tranylcypromine 65-80 monoamine oxidase A Homo sapiens 32-37 24601544-5 2014 The energy for 2-BFI binding to MAO A was comparable to that for tranylcypromine-modified MAO B, but the location of 2-BFI in the MAO A could be anywhere in the monopartite substrate cavity. Tranylcypromine 65-80 monoamine oxidase A Homo sapiens 130-135 17367163-7 2007 2-PCPA shows limited selectivity for human MAOs versus LSD1, with kinact/KI values only 16-fold and 2.4-fold higher for MAO B and MAO A, respectively. Tranylcypromine 0-6 monoamine oxidase A Homo sapiens 130-135